NASDAQ NMS - GLOBAL MARKET · ZNTL
+5.19% · +$0.1600 · Vol 1.3M
Market closed · last close 4:00 PM ET · price as of 19:50:59 ET
Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Biotechnology
$3.24
Card
Relationship Map

Follow $ZNTL

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ZNTL by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Earnings absence reason unknown · Analyst data unavailable at compute time
ZNTL
Zentalis Pharmaceuticals Inc
Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

53/ 100
Veridion Score
Middle range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4 of 6 factors measured · Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ZNTL moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ZNTL catalysts
About Zentalis Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
106
Country
US

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.07
Day high
$3.18
Day low
$2.99
Previous close
$3.08
52W high
$6.61
-50.98% from high
52W low
$1.28
37% of range
Market cap
$291.6M
EPS
$-1.8300
Beta
1.33
Shares out
94.7M
Volume
1.3M
1.17× rel vol
Avg volume
1.1M
VWAP
$3.10
Price history computed in-house
1W
-7.69%
1M
-15.62%
3M
-12.43%
1Y
+113.16%
YTD
+140.00%
SMA 50 $4.15 · below
SMA 200 $3.35 · below
52W position 37%

ZNTL overview

Veridion Score
53
Registered · 2026-09-18
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ZNTL.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ZNTL Form 4 filings
Public disclosures

Congress activity in ZNTL

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ZNTL in the cached public ledger.

Federal contracts

ZNTL contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ZNTL in this window.
Lobbying spend

ZNTL lobbying filings, year to date.

Registered lobbying filings matched to Zentalis Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ZNTL in this window.
Loading news for ZNTL
Analyst ratings
Sovereign unlock shows live analyst consensus for ZNTL.
Options
Sovereign unlock shows live options positioning for ZNTL.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.